Mytolac (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Mytolac, is a somatostatin analog presented as a sterile injectable solution for subcutaneous use. It is employed to manage hormone‑secreting tumors and growth‑hormone disorders in adult patients, including conditions such as acromegaly and carcinoid syndrome.

GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance for global markets. Our distribution network ensures timely delivery to clinical sites across Europe, Asia and the Americas.

Mytolac, a somatostatin analog, is used to control hormone‑secreting tumors and related endocrine disorders.

Acromegaly: reduces excess growth hormone and IGF‑1 levels, improving symptoms and associated metabolic complications. Neuroendocrine tumors (carcinoid syndrome): decreases secretion of vasoactive peptides, alleviating flushing, diarrhea and abdominal pain. Cushing's disease (off‑label): lowers ACTH production, helping to control cortisol excess.

Mytolac may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Diarrhea or abdominal discomfort - Headache - Hyperglycemia or altered glucose tolerance - Fatigue

Serious or Rare Side Effects: - Gallbladder disease, including cholelithiasis - Acute pancreatitis - Severe hyperglycemia or diabetic ketoacidosis - Allergic reactions such as anaphylaxis - Cardiovascular events (e.g., arrhythmia, ischemia) - Pituitary apoplexy in patients with pre‑existing adenomas

Before initiating Mytolac, clinicians should consider several safety measures.

Monitor glucose: patients with diabetes may experience altered blood‑sugar control. Assess gallbladder: increased risk of gallstones; consider baseline imaging. Evaluate pancreatic function: watch for signs of pancreatitis. Review cardiac status: use cautiously in patients with known heart disease. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mytolac can interact with other medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - Concomitant cyclosporine: may increase lanreotide exposure. - Use with other somatostatin analogs: additive hormonal suppression. - Combination with insulin or sulfonylureas: risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Co‑administration with dopamine agonists: potential additive endocrine effects. - Oral contraceptives: possible reduced efficacy. - Warfarin or other anticoagulants: monitor INR and adjust dose as needed.